Loading
Principal investigator of CROWN, where lorlatinib produced the longest disease control ever recorded for a targeted lung cancer pill.
Benjamin Solomon is Professor of Medical Oncology and Head of Lung Medical Oncology at the Peter MacCallum Cancer Centre in Melbourne. He led the PROFILE 1014 and CROWN trials, which established crizotinib and then lorlatinib as treatments for ALK-positive non-small-cell lung cancer, and CROWN produced the longest disease control recorded for a targeted lung cancer pill. His publications include the five-year outcomes of lorlatinib against crizotinib in advanced ALK-positive disease. He directs thoracic medical oncology and lung cancer research at Peter Mac, with interests in ALK inhibitors, targeted therapy and clinical trials.
| Title | Journal | Year |
|---|---|---|
| Lorlatinib versus crizotinib in patients with advanced ALK-positive NSCLC: 5-year outcomes from CROWN | Journal of Clinical Oncology | 2024 |
| CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer | New England Journal of Medicine | 2020 |
Shares CROWN, Lorlatinib, ALK-positive non-small-cell lung cancer, ALK.
Shares CROWN, First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer, Lorlatinib, ALK-positive non-small-cell lung cancer.
Shares Lorlatinib, ALK-positive non-small-cell lung cancer, ALK, Non-small-cell lung cancer.
Shares First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer, Lorlatinib, ALK, Non-small-cell lung cancer.
Shares CROWN, Lorlatinib, ALK, Non-small-cell lung cancer.
Shares Lorlatinib, ALK-positive non-small-cell lung cancer, ALK, Non-small-cell lung cancer.
Shares International Association for the Study of Lung Cancer, ALK, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, ALK, Non-small-cell lung cancer.